<span id="midArticle_start"/> Pharming Group NV :
<span id="midArticle_0"/>* Announces interim results from the ongoing phase IIpediatric clinical trial of RUCONEST
<span id="midArticle_1"/> <span class="first-article-divide"/>* Interim data from ongoing pediatric clinical trial andresults from a clinical immunology study support safety andefficacy of RUCONEST
<span id="midArticle_2"/> <span class="second-article-divide"/>* Several abstracts presented demonstrate Pharming's ongoingcommitment to advance innovative science in HereditaryAngioedema (HAE)
<span id="midArticle_3"/> <span class="third-article-divide"/>* "These data add to our clinical database andpost-marketing experience that demonstrate a very low risk ofallergy with rhC1INH exposure" - Chief Operating officerSource text for Eikon: Further company coverage: (Gdynia Newsroom)
<span id="midArticle_4"/>
<span id="midArticle_0"/>* Announces interim results from the ongoing phase IIpediatric clinical trial of RUCONEST
<span id="midArticle_1"/> <span class="first-article-divide"/>* Interim data from ongoing pediatric clinical trial andresults from a clinical immunology study support safety andefficacy of RUCONEST
<span id="midArticle_2"/> <span class="second-article-divide"/>* Several abstracts presented demonstrate Pharming's ongoingcommitment to advance innovative science in HereditaryAngioedema (HAE)
<span id="midArticle_3"/> <span class="third-article-divide"/>* "These data add to our clinical database andpost-marketing experience that demonstrate a very low risk ofallergy with rhC1INH exposure" - Chief Operating officerSource text for Eikon: Further company coverage: (Gdynia Newsroom)
<span id="midArticle_4"/>
via Smart Health Shop Forum http://ift.tt/1d8J4SF
No comments:
Post a Comment